Cilostamide
Cilostamide structure
|
Common Name | Cilostamide | ||
|---|---|---|---|---|
| CAS Number | 68550-75-4 | Molecular Weight | 342.432 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 594.3±50.0 °C at 760 mmHg | |
| Molecular Formula | C20H26N2O3 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 313.2±30.1 °C | |
Use of CilostamideCilostamide is a selective and potent PDE3 inhibitor, with IC50s of 27 nM and 50 nM for PDE3A and PDE3B, respectively, and has antithrombotic and anti-intimal hyperplastic activity. |
| Name | Cilostamide |
|---|---|
| Synonym | More Synonyms |
| Description | Cilostamide is a selective and potent PDE3 inhibitor, with IC50s of 27 nM and 50 nM for PDE3A and PDE3B, respectively, and has antithrombotic and anti-intimal hyperplastic activity. |
|---|---|
| Related Catalog | |
| Target |
IC50: 27 nM (PDE3A), 50 nM (PDE3B)[1] |
| In Vitro | Cilostamide is a selective and potent PDE3 inhibitor, with IC50s of 27 nM and 50 nM for PDE3A and PDE3B, respectively, and has antithrombotic and anti-intimal hyperplastic activity. Cilostamide weakly inhibits PDE2, PDE4, PDE5, PDE7, and PDE1, with IC50s of 12.5, 88.8, 15.2, 22.0 and > 300 μM, respectively. Cilostamide potently inhibits thrombin-induced platelet aggregation (IC50, 1.1 μM)[1]. |
| Animal Admin | Platelet aggregation is investigated in the assay. Washed platelets (200 μL of a suspension containing 3 × 108 cells/mL in Tyrode HEPES buffer, pH 7.4) are incubated for 3 min at 37°C in the presence or absence of different concentrations of OPC-33540, OPC-33536, and Cilostamide alone, or in combination with 3 nM PGE1, followed by incubation with 5 μL of 2 units/mL of thrombin for 5 min at 37°C. The intensity of light transmitted over 5 min is measured using a PAM-8C aggregometer. The inhibition rate is calculated by comparison of maximum aggregation rates with the control value[1]. |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 594.3±50.0 °C at 760 mmHg |
| Molecular Formula | C20H26N2O3 |
| Molecular Weight | 342.432 |
| Flash Point | 313.2±30.1 °C |
| Exact Mass | 342.194336 |
| PSA | 62.40000 |
| LogP | 2.70 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.586 |
| Storage condition | -20℃ |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | UN 3249 |
| Packaging Group | III |
| Hazard Class | 6.1(b) |
CAS#:100-60-7![4-[(2-oxo-1H-quinolin-6-yl)oxy]butanoic acid Structure](https://www.chemsrc.com/caspic/072/58899-33-5.png)
CAS#:58899-33-5
CAS#:42454-06-8![N-cyclohexyl-N-methyl-4-[3-(2-carboxyvinyl)-4-nitrophenoxy]butyramide Structure](https://www.chemsrc.com/caspic/231/105763-50-6.png)
CAS#:105763-50-6
CAS#:94193-36-9
CAS#:19315-93-6|
Different compartmentation of responses to brain natriuretic peptide and C-type natriuretic peptide in failing rat ventricle.
J. Pharmacol. Exp. Ther. 350(3) , 681-90, (2014) We previously found a negative inotropic (NIR) and positive lusitropic response (LR) to C-type natriuretic peptide (CNP) in the failing heart ventricle. In this study, we investigated and compared the... |
|
|
Adenylyl cyclases 5 and 6 underlie PIP3-dependent regulation.
FASEB J. 29 , 3458-71, (2015) Many different neurotransmitters and hormones control intracellular signaling by regulating the production of the second messenger cAMP. The function of the broadly expressed adenylyl cyclases (ACs) 5... |
|
|
Lymphatic vascular integrity is disrupted in type 2 diabetes due to impaired nitric oxide signalling.
Cardiovasc. Res. 107 , 89-97, (2015) Lymphatic vessel dysfunction is an emerging component of metabolic diseases and can lead to tissue lipid accumulation, dyslipidaemia, and oedema. While lymph leakage has been implicated in obesity and... |
| Butanamide, N-cyclohexyl-4-[(1,2-dihydro-2-oxo-6-quinolinyl)oxy]-N-methyl- |
| N-Cyclohexyl-N-methyl-4-[(2-oxo-1,2-dihydro-6-quinolinyl)oxy]butanamide |
| MFCD00673958 |
| N-Cyclohexyl-N-methyl-4-[(2-oxo-1,2-dihydroquinolin-6-yl)oxy]butanamide |
| N-cyclohexyl-N-methyl-4-[(2-oxo-1H-quinolin-6-yl)oxy]butanamide |
| N-cyclohexyl-4-[(2-hydroxyquinolin-6-yl)oxy]-N-methylbutanamide |